(

)

Stockholders

Equity

$10.5

Million Registered Direct Offering - On

December 15, 2020,

the Company entered into a securities purchase agreement with certain institutional investors (the

December 15

Purchase Agreement) for the sale of an aggregate of

2,038,836

shares (the

December 15

Shares) of the Company's common stock,

$0.001

par value per share (the Common Stock), at a price to the public of

$5.15

per share (the

December 15

Registered Offering) share for gross proceeds of approximately

$10.5

million before deducting the fees of A.G.P./Alliance Global Partners, which acted as placement agent, and related offering expenses. The Company paid the placement agent a cash fee equal to

7.0%

of the gross proceeds generated from the sale of the

December 15

Shares. On

December 18, 2020,

BioCardia concluded the Purchase Agreement with the purchasers of the

December 15

Shares. The Company intends to use the net proceeds for working capital and general corporate purposes, which include, but are

not

limited to, completing enrollment in the ongoing CardiAMP Cell Therapy pivotal trial for the treatment of heart failure, the funding of clinical development and pursuing regulatory approval for BioCardia's product candidates. After deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, BioCardia realized net proceeds of approximately

$9.8

million. The

December 15

Offering was made pursuant to a Registration Statement on Form S-

which was filed by the Company with the Securities and Exchange Commission on

October 9, 2020,

and declared effective on

October 20, 2020,

as supplemented by a prospectus supplement dated

December 15, 2020.

$8.5

Million Registered Direct Offering

- On

December 14, 2020,

the Company entered into a securities purchase agreement with certain institutional investors (the

December 14

Purchase Agreement) for the sale of an aggregate of

1,789,474

shares (the

December 14

Shares) of the Company's common stock,

$0.001

par value per share (the Common Stock), at a price to the public of

$4.75

per share (the

December 14

Registered Offering) for gross proceeds of approximately

$8.5

million before deducting the fees of A.G.P./Alliance Global Partners, which acted as placement agent, and related offering expenses. The Company paid the placement agent a cash fee equal to

7.0%

of the gross proceeds generated from the sale of the

December 14

Shares and reimbursed the Placement Agent for certain of its expenses in an amount

not

to exceed

$40,000.

December 16, 2020,

BioCardia concluded the Purchase Agreement with the purchasers of the

December 14

Shares. The Company intends to use the net proceeds for working capital and general corporate purposes, which include, but are

not

$7.8

million. The

December 14

Offering was made pursuant to a Registration Statement on Form S-

which was filed by the Company with the Securities and Exchange Commission on

October 9, 2020,

and declared effective on

October 20, 2020,

as supplemented by a prospectus supplement dated

December 14, 2020.

2020

Public Offering on Form S-

Registration Statement -

May 2020,

the Company submitted a Form S-

Registration Statement (S-

) to the SEC, which was subsequently amended. On

June 17, 2020,

the Company entered into an underwriting agreement with A.G.P./Alliance Global Partners, as representative of the several underwriters named therein, relating to a firm commitment underwritten public offering pursuant to the S-

4,762,000

shares of common stock, par value of

$0.001

per share. The offering price to the public was

$2.10

per share. The underwriters were granted a

-day option to purchase up to

714,190

additional shares of common stock to cover over-allotments. Such option was exercised in full on

June 18, 2020.

The closing of the offering occurred on

June 19, 2020.

After deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, BioCardia realized net proceeds of approximately

$10.3

million.

June 8, 2020,

the Company issued

29,625

shares of common stock to

two

former Board members to settle in lieu of cash their accrued board compensation liability of approximately

$148,000.

Public Offering on Form S-

Registration Statement

- In

April 2019,

the Company submitted a Form S-

Registration Statement (S-

) to the SEC, which was subsequently amended. On

August 2, 2019,

the Company entered into an underwriting agreement with Maxim Group LLC, as representative of the several underwriters named therein, relating to a firm commitment underwritten public offering pursuant to the S-

1,666,667

units consisting of

one

share of common stock, par value of

$0.001

per share, and a warrant to purchase

one

share of common stock. The offering price to the public was

$6.00

per unit. The warrants, which are equity classified, are immediately exercisable for shares of common stock at a price of

$6.30

per share and expire

five

years from the date of issuance. In addition, the underwriters were granted

11,958

warrants exercisable at a per warrant exercise price of

$6.60

as part of their compensation. The underwriters were granted a

-day option to purchase up to

250,000

additional shares of common stock, and/or

250,000

additional warrants to cover over-allotments, if any. The closing of the offering occurred on

August 6, 2019.

After deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, BioCardia realized net proceeds of approximately

$8.8

million. On

September 4, 2019,

the underwriters exercised the over-allotment and purchased

75,000

shares of common stock and

250,000

warrants for net proceeds of approximately

$420,000,

after deducting underwriting discounts of approximately

$32,000.

Up List to Nasdaq

- On

August 2, 2019,

the Company's common stock and warrants to purchase common stock began trading on the Nasdaq Capital Market. Previously, the common stock was quoted on the OTCQB Marketplace (OTCQB) under the symbol, “BCDA.” “BCDA” and “BCDAW” are the trading symbols for the Company's common stock and warrants to purchase common stock, respectively, on the Nasdaq Capital Market.

Convertible Note Financing

- On

July 5, 2019,

BioCardia entered into a note purchase agreement pursuant to which the Company issued on such date

$625,000

in aggregate principal amount of convertible promissory notes to accredited investors, a portion of which were certain of the Company's officers and directors and a principal stockholder (or their respective affiliates). The notes accrued

14.0%

simple interest and mature

six

months from the issue date, on

January 5, 2020.

If at any time prior to the maturity date, the Company closes a public stock offering for the purpose of raising capital in which the Company's common stock is listed or quoted on the New York Stock Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market, the outstanding principal and interest would automatically convert into the securities offered in the financing at a unit price equal to a

50%

discount to the qualified financing price. The convertible notes conversion features were determined to be an embedded derivative requiring bifurcation and separate accounting at estimated fair value. The fair value of the derivative was treated as a discount on the notes, which is subject to accretion over the term of the note. The change in fair value of the derivative liability was approximately

$52,000.

The loss on extinguishment of the convertible notes approximated

$521,000.

Interest expense on the notes for the year ended

December 31, 2019

totaled

$112,000

and included

$104,000

of accretion of the discount.

Upon the closing of the Company's public offering of units on

August 6, 2019

the unpaid principal and interest on the convertible notes totaling approximately

$633,000,

converted into

210,887

units, each unit consisting of

one

share of common stock and a warrant to purchase

one

share of common stock, at a conversion price of

$3.00

per unit. Holders of the convertible notes had the option of converting the notes into units of

one

share of common stock and a warrant at a unit price of

$8.00

prior to the automatic conversion in the Company's public offering. The warrants have the same terms, including exercise price and expiration date, as the warrants issued in the public offering.

Reverse Stock Split

- On

June 6, 2019,

the Company effected a

-for-

reverse stock split of the Company's common stock. Neither the par value nor the authorized number of shares was adjusted as a result of the reverse stock split. All issued and outstanding common stock, warrants, stock options, restricted stock units and per share amounts contained in the accompanying consolidated financial statements and notes to the consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.

Sales of Unregistered Common Stock and Warrants

- On

December 24, 2018,

the Company entered into a Securities Purchase Agreement with entities affiliated with BioCardia's existing investors (the “Investors”), relating to an offering and sale of an aggregate of

592,592

shares (as adjusted) of the Company's common stock at a purchase price of

$6.75

per share (as adjusted), and warrants to purchase up to

one

-half of the number of shares of common stock sold to an Investor, up to an aggregate for all Investors of

296,296

shares (as adjusted) of common stock, for aggregate net proceeds of

$3.8

million net of

$200,000

expenses. The warrants are exercisable immediately for cash and, because

six

months have passed, are also exercisable on a cashless basis until an effective registration statement has been filed registering the resale of the shares issuable upon exercise of the warrants. As of

December 31, 2020,

effective registration statement had been filed. Warrants can be settled in unregistered shares. The warrants have an exercise price of

$6.75

per share and will expire on

December 24, 2023.

The issued warrants are stand-alone financial instruments and were equity classified in additional paid-in capital in accordance with U.S. GAAP.

Warrants

– Set forth below is a table of activity of warrants for common stock and the related weighted average exercise price per warrant.

	Number of			Weighted
	Common Stock			Average
	Warrants			Exercise Price
Balance, December 31, 2019		2,435,807		$	6.36
Warrants for common stock sold		—			—
Warrants for common stock exercised		(11,083	)		6.60
Balance, December 31, 2020		2,424,724		$	6.36

December 24, 2020,

a warrant holder exercised

11,083

warrants for common stock using cashless exercise provisions, resulting in the issuance of

470

shares of common stock.